Andrew Ahmann
0000-0002-4544-5404
1 paper found
Refreshing results…
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Missing publications? Search for publications with a matching author name.